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This study was undertaken to determine the value of tumour microvessel density (MVD) and the expression of p53 and vascular
endothelial growth factor (VEGF) as prognostic markers in patients with gastric cancer operated on for cure. In all, 156 patients with
curatively resected gastric cancer constituted the basis of this blinded retrospective evaluation. Patients were treated with either
surgery alone (n¼53) or surgery plus adjuvant chemotherapy (n¼103). Tumour MVD, p53 expression, and VEGF expression were
assayed using immunohistochemical techniques. After a mean follow-up of 43 months, 64 (41%) patients had died and 55 (35%)
patients developed tumour recurrence. Positive correlations between MVD and both p53 (P¼0.005) and VEGF (P¼0.005)
expression were observed. Both MVD X100 (P¼0.05) and positive VEGF expression (Po0.02) were associated with shorter
disease-free survival, and positive VEGF expression (P¼0.01) was also associated with shorter overall survival. Multivariate analysis
confirmed that, in addition to the pathological tumour stage, lymph node ratio, the extent of lymphadenectomy and perineural
invasion, p53 expression, and VEGF expression were independently associated with both disease-free survival (Po0.0005 and 0.02,
respectively) and overall survival (Po0.02 and 0.01, respectively). Finally, patients whose tumours did not show p53 expression had a
survival benefit compared to those expressing p53 when treated with adjuvant chemotherapy (P¼0.01).This investigation
demonstrates that p53 expression and VEGF expression are independent prognostic factors for both disease-free survival and overall
survival in patients with curatively resected gastric cancer, and that p53 status may also influence response to chemotherapy.
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Until the 1980s, gastric cancer was one of the most frequent
tumours in the world and the leading cause of cancer death (Parkin
et al, 1999). In recent decades, the incidence has declined, but the
prognosis of gastric cancer in the Western countries has not
improved, the 5-year survival being 20–30% (Hundahl et al, 2000;
Greenlee et al, 2001). Surgical resection is the most powerful tool
to improve prognosis, whereas the major problem is delayed
diagnosis resulting in advanced disease. In most American and
European series, almost 60% of operated patients have patholo-
gical tumour (pT) stages 3 and 4. Screening programmes are not
usually performed due to their high cost and minimal benefit in
decreasing mortality rates (Lacueva and Calpena, 2001).
In curatively resected patients, the biologic nature of the tumour
determines survival since almost half will die from recurrent
cancer (Averbach and Jacquet, 1996). The poor prognosis of
patients with recurrent disease is due to the lack of an effective
rescue treatment. In fact, the number of patients with recurrent
gastric cancer in which it is feasible to perform curative surgery is
less than 4% (Yoo et al, 2000). It seems necessary to evaluate new
biological markers that may predict the natural history of the
disease as a guide to treatment. Newer tumour markers include
tumour suppressor gene p53, vascular endothelial growth factors
(VEGFs), and microvessel density (MVD) as a measure of new
blood vessel growth or angiogenesis. Without blood vessels,
tumours cannot grow beyond a critical mass nor create metastases
(Castells and Rustgi, 2003). A hypoxic environment and genetic
instability in the centre of the tumour allows the evolution of
cellular clones with the loss of p53 function. These cells have a
lower apoptotic rate and produce angiogenic factors like VEGF,
inducing new vasculature (Harris, 1997). These factors might
provide information to help predict the prognosis of patients with
gastric cancer. However, the prognostic value of p53 expression in
these patients is controversial (Gabbert et al, 1995), although it has
been related to the development of higher MVD (Maehara et al,
2000b). The expression of VEGF has been associated with vascular
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yinvasion, liver metastases (Takahashi et al, 1996), and lymph node
metastases (Maeda et al, 1996). Inhibition of the VEGF pathway
using monoclonal antibodies has shown potent antitumour effects
in animal models (Witte et al, 1998), and this might be a new
approach to treat these patients in the future.
The use of adjuvant chemotherapy in gastric cancer is still
controversial and has been reviewed in several meta-analyses
(Hermans et al, 1993; Earle and Maroun, 1999). One review
concluded that adjuvant chemotherapy produced marginal benefit
in the survival of curatively resected patients (Earle and Maroun,
1999), but it is clearly necessary to find more effective treatments.
Differing responses to chemotherapy may be due to biological
characteristics of the tumour such as p53 status, since p53-
dependent apoptosis modulates the cytotoxic effects of antitumour
agents such as 5-fluorouracil, doxorubicin, and cisplatin (Chin
et al, 1992; Lowe et al, 1993), commonly used as adjuvant therapy.
Knowing the p53 status of the individual patient might allow us to
select those cases most likely to respond to adjuvant therapy.
The aim of this study was (1) to investigate whether MVD as well
as p53 expression and VEGF expression are independent prog-
nostic factors for patients with gastric cancer undergoing curative
gastrectomy, and (2) to evaluate their predictive value for clinical
outcome following adjuvant chemotherapy.
PATIENTS AND METHODS
A consecutive series of 206 patients with primary gastric cancer
received surgical treatment at our hospital between January 1989
and October 1998. The mean age was 67712 years (range: 23–93
years), and 130 (63%) patients were male. Of them, 164 (80%)
patients underwent potentially curative resection (R0 resection
following UICC criteria
18), defined as macroscopically and
microscopically complete removal of the tumour on intraoperative
and histopathologic evaluation. Eight patients (5%) died within 60
days after surgical treatment and were excluded from this analysis.
Accordingly, 156 patients constituted the basis of the study.
The characteristics of patients included in the study are shown
in Table 1. Staging and grading were referred to the fifth edition of
the tumour-node metastasis (TNM) classification of the Interna-
tional Union Against Cancer (UICC) (Sobin and Fleming, 1997).
Accordingly, 19 patients (12%) were classified as UICC stage IA, 39
(25%) as stage IB, 42 (27%) as stage II, 27 (17%) as stage IIIA, 21
(13%) as stage IIIB, and eight (5%) as stage IV.
The surgical technique in this group was as follows: 76 subtotal
gastrectomies (49%), 77 total gastrectomies (49%), and three
stump gastrectomies (2%). Based on the decision of the surgeon,
50 (32%) patients had a D1 lymphadenectomy, including the first-
level lymph nodes (paracardial, major and minor curvature,
supra-, and infrapyloric) and 106 (68%) patients had a D2
lymphadenectomy, in which the second-level nodes (left gastric
artery, hepatic artery, celiac trunk, splenic hilum, and splenic
artery) were also excised. Splenectomy to ensure complete
resection of the tumour was performed in 49 patients (31%). A
perioperative histological frozen section of the resection margin
was always performed to rule out tumour invasion.
In all, 103 patients (66%) received adjuvant chemotherapy based
on either mitomycin C (10–20mg/m
2 i.v. every 6 weeks) (n¼38)
or mitomycin C (10–20mg/m
2 i.v. on day 1 every 6 weeks) plus
tegafur (500mg/m
2day
1 for 36 consecutive days) (n¼65). The
courses were repeated four times as reported previously (Grau et al,
1998).
Follow-up
Patients were followed up at 3-month intervals over the first 2
years, and at 6-month intervals thereafter. Medical work-up
consisted of history and physical examination, haematology and
biochemical tests, including serum carcinoembryonic antigen,
carbohydrate antigen 19-9, and tissue-associated glycoprotein 72-4
concentration, and chest radiography, abdominal ultrasonography,
and endoscopy. If local tumour recurrence and/or metastasis were
suspected, the confirmation of the diagnosis by biopsy or a second
surgical exploration was attempted.
Table 1 Demographic, clinical, and tumor characteristics of patients
included in the study (n¼156)
Age (years)
o70 88 (56%)
X70 68 (44%)
Gender
Male 101 (65%)
Female 55 (35%)
Tumour location
Cardiac fundus 11 (7%)
Body 62 (40%)
Antrum pylorus 80 (51%)
Diffuse 3 (2%)
Lauren classification
Intestinal 97 (62%)
Diffuse 59 (38%)
Tumour size (mm) 54727
Degree of differentiation
Well 6 (4%)
Moderate 73 (47%)
Poor 77 (49%)
Signet-ring cell-type
tumours
41 (26%)
pT stage
a
T1 28 (18%)
T2 75 (48%)
T3 51 (33%)
T4 2 (1%)
pN stage
a
N0 66 (42%)
N1 54 (35%)
N2 33 (21%)
N3 3 (2%)
Lymph-node ratio
b
0 66 (42.3%)
o30% 48 (30.8%)
X30% 42 (26.9%)
Lymphatic invasion 44 (28.2%)
Vascular invasion 17 (10.9%)
Perineural invasion 20 (12.8%)
pM stage
a
M0 151 (96.8%)
M1 5 (3.2%)
pTNM tumor stage
a
IA 19 (12.2%)
IB 39 (25%)
II 42 (26.9%)
IIIA 27 (17.3%)
IIIB 21 (13.5%)
IV 8 (5.1%)
aAccording to the 5th edition of the tumour-node metastasis classification of the
International Union Against Cancer (UICC)
18.
bNumber of affected lymph nodes
divided by the total number of lymph nodes. pT¼pathological tumour;
pTNM¼pathological tumour node metastasis. pN¼pathological lymph node;
pM¼pathological metastasis.
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Paraffin-embedded tissue blocks of formalin-fixed surgically
resected samples were processed for conventional histological
study and for immunohistochemical analysis. Immunohistochem-
ical studies were performed using the automated immunohisto-
chemical system TechMate 500 (Dako, Carpinteria, CA, USA),
using the EnVision system (Dako). Briefly, 4mm-thick sections
were deparaffinised and hydrated through graded alcohol and
water. Peroxidase was blocked for 7.5min in ChemMate perox-
idase-blocking solution (Dako). Then the slides were incubated
with the primary antibodies for 30min and washed in ChemMate
buffer solution (Dako). The peroxidase-labelled polymer was then
applied for 30min. After washing in ChemMate buffer solution, the
slides were incubated with the diaminobenzidine substrate
chromogen solution, washed in water, counterstained with
haematoxylin, washed, dehydrated, and mounted. Antigen retrie-
val was performed in citrate buffer, pH 6.0, in a pressure cooker.
The following antibodies were used in this study: monoclonal
antibody against p53 (clone BP53-12 at a 1:50 dilution,
Novocastra, Newcastle upon Tyne, UK), polyclonal antibody
against VEGF (clone A-20 at a 1:300 dilution, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), and a monoclonal antibody
against the CD34 antigen (clone QBEnd/10 at a 1:200 dilution;
Novocastra, Newcastle upon Tyne, UK).
p53 staining analysis Using a light microscope, a visual grading
system based on the number of positively stained nuclei of
the malignant cells in each tissue was used (Figure 1). If 10%
or more of the malignant nuclei were stained, the slide was scored
as positive. If fewer than 10% of the nuclei were stained, the slide
was scored as negative, in accordance with other authors (Kakeji
et al, 1993; Maehara et al, 1999). All specimens were analysed
by two separate investigators (CF and AV) who were blinded
to all clinical information. Conflicts in scores were resolved by
consensus.
VEGF staining analysis Vascular endothelial growth factor
immunostaining was considered to be positive when unequivocal
cytoplasmic staining was seen in the tumour cells, regardless
of the number of cells stained. Vascular endothelial growth factor
expression was analysed in the invasive front of the tumour away
from the tumour centre where necrosis and hypoxia may induce
VEGF expression. The intensity of staining for VEGF was graded as
follows:  , no detectable expression; þ, moderate stain; þþ,
strongest stain under a  250 field (Figure 2). As described by
Inoue et al (1997), we used smooth muscle cells as a positive
internal control. Two different investigators (CF and AV) assessed
the degree of staining without knowledge of the clinical data.
Microvessel staining and counting Quantitative vessel counts
were performed by the method described by Weidner and assessed
by international consensus (Vermeulen et al, 1996). The entire
tumour sections were systematically scanned at  40 magnifica-
tion to find the areas of most intense neovascularisation or hot
spots. These were identified as having the highest density of brown
staining, CD34-positive cells, or cell clusters. For each slide,
the most vascular areas within the tumour mass were chosen
(Figure 3). A  250 field in these areas was counted, and the
average counts of the fields were recorded. If multiple vascular
hot spots were present, counts were performed in each hot
spot. Microvessels were defined as a discrete CD34-positive
endothelial cell aggregate, with or without definable lumina. The
microvessels were counted by two investigators (CF and AV) who
had no knowledge of the other prognostic factors and/or clinical
outcomes.
Statistical methods
The relationship between tumour MVD, p53 expression, and VEGF
expression, as well as their correlation with clinicopathological
parameters were evaluated by the w
2 test. The length of follow-up
Figure 1 Diffuse-type gastric cancer with signet ring nucleus. (A and B) No expression of p53. (C and D) Intense staining in the irregular nucleus of
tumour cells.
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range. The impact of single parameters on prognosis (tumour
recurrence, disease-free survival, and overall survival) was
determined by both univariate and multivariate approaches.
Tumour recurrence was evaluated by means of logistic regression
analysis. Probabilities of disease-free survival and overall survival
were calculated according to the Kaplan–Meier method and
compared with the log-rank test. Variables achieving a significance
Figure 2 Two samples of gastric tumours with expression of VEGF: A (þ), B (þþ). The VEGF appears in the cytoplasm of cells. In (B) the intensity is
higher than in (A). The evaluation was carried out in the tumour margins far from the tumour centre where the hypoxia can induce VEGF expression.
Figure 3 Evaluation of tumour angiogenesis. Identification of external border of tumour growth at  40 (A) and  100 (B) magnification field: I
(desmoplastic stroma), II (infiltration zone), and III (tumour). At  250 magnification field (C and D), it is possible to appreciate the differences in the degree
of MVD between tumours.
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ylevel of Pp0.1 in the univariate analysis were subsequently
introduced in a forward stepwise proportional-hazard analysis
(Cox’s model) to identify those variables independently associated
with survival. Disease-free survival was established from the time
of surgery to the date when recurrence or death was detected.
Overall survival was established from the date of surgery to death
from any cause or the date of the last follow-up visit. In both cases,
patients who were event free at the end of follow-up were censored
at that time. For continuous variables (i.e. MVD and lymph node
ratio), the cut-off level chosen was their median value. Vascular
endothelial growth factor categories were reclassified as negative
and positive (including moderate and strong staining) for
statistical purposes. Variables actually reflecting a combination
of independent parameters (i.e. TNM stage) were not included in
the multivariate analysis as a single covariable, but rather
decomposed in the corresponding original counterparts (T, N,
and M components). All statistical analyses were performed two-
sided at a significance level of P¼0.05, using the statistical
package SPSS (SPSS Inc., Chicago, IL, USA).
RESULTS
After a mean follow-up of 43 months (95% CI: 37–49 months;
range: 2–191 months), 64 (41%) patients had died, the prob-
ability of survival being 69 and 54% at 2 and 5 years, respectively.
A total of 50 patients died because of tumour progression and
14 due to other causes. In all, 55 (35%) patients developed
tumour recurrence, 33 of whom presented as locoregional relapse,
12 as distant metastases (eight in liver, three in lung, and one in
bone), nine as peritoneal seeding, and one as stump. All but three
patients with tumour recurrence died from it.
Correlation between MVD, p53 expression, and VEGF
expression
The median microvessel count was 98.9. (95% CI: 94.7–103.2), and
this value was used to dichotomise the series. p53 expression was
detected in 71 (46%) patients (Table 2). p53 protein expression
was significantly associated with MVD X100 (OR: 2.22, 95% CI:
1.26–3.88; P¼0.005).
Vascular endothelial growth factor expression was detected in
116 (74%) patients (Table 2). There was a significant association
with MVD X100 (OR: 2.65, 95% CI: 1.33–5.29; P¼0.005). There
was no association between p53 and VEGF expression.
Correlation between MVD, p53 expression, and VEGF
expression, and clinicopathological characteristics
Neither p53 positivity nor VEGF expression was related to any of
the clinicopathological parameters reported in Table 1. On the
contrary, a statistically significant association was found between
MVD X100 and lymph node metastases (Po0.003). As shown in
Table 3, the lymph node ratio was also higher when MVD was
elevated (Po0.02), as well as the pN stage (Po0.003).
Tumour recurrence and disease-free survival
There were statistically significant associations between tumour
recurrence and tumour MVD X100, p53 expression, and VEGF
expression (Table 4). Other significant parameters found in the
univariate analysis of tumour recurrence were pT stage
(Po0.0001), pN stage (Po0.0001), pTNM stage (Po0.0001),
lymph node ratio (Po0.0001), lymphatic invasion (Po0.0001),
Lauren classification (Po0.005), signet-ring cell-type tumours
(Po0.013), degree of differentiation (Po0.008), and extent of
lymphadenectomy (Po0.0001).
Both MVD X100 (P¼0.05) and VEGF expression (Po0.02)
were associated with a shorter disease-free survival in the
univariate analysis (Table 4). Other significant parameters found
in the analysis of disease-free survival were pT stage (Po0.0001),
pN stage (Po0.0001), pTNM stage (Po0.0001), lymph node ratio
(Po0.0001), lymphatic invasion (Po0.0001), Lauren classification
(Po0.0039), signet-ring cell-type tumours (Po0.01), degree of
differentiation (Po0.0048), and extent of lymphadenectomy
(Po0.0001). No correlation between MVD, p53 expression, and
VEGF expression, and the type of recurrence (locoregional relapse
vs distant metastases) was found.
The multivariate analysis identified lymph node ratio X30%, D1
lymphadenectomy, p53 expression, and VEGF expression as
independent predictors of tumour recurrence and disease-free
survival (Table 5).
Overall survival
In the univariate analysis, factors influencing overall survival were
pTNM stage (Po0.0001), pT (Po0.0001), pN (Po0.0001), lymph
node ratio (Po0.0001), signet-ring cell-type tumours (Po0.01),
degree of differentiation (Po0.005), Lauren classification
(Po0.005), lymphatic invasion (Po0.0001), perineural invasion
(Po0.39), and extent of lymphadenectomy (Po0.0001). In
addition, VEGF expression was associated with a shorter overall
survival (HR: 2.48, 95% CI: 1.16–5.28; P¼0.01) (Figure 4). By
contrast, neither p53 expression (HR: 1.61, 95% CI: 0.93–2.80;
P¼0.08) nor MVD X100 (HR: 1.70, 95% CI: 0.95–3.02; P¼0.07)
reached statistical significance in this analysis.
The multivariate Cox’s regression analysis revealed that pT3
stage or higher, lymph node ratio X30%, D1 lymphadenectomy,
Table 2 Distribution of tumour microvessel density, p53 expression, and
VEGF expression in patients included in the study (n¼156)
Tumor microvessel density
o100 74 (47.4%)
X100 82 (52.6%)
p53 expression
Negative 85 (54.5%)
Positive 71 (45.5%)
VEGF expression
Negative 40 (25.6%)
Positive+ 83 (53.2%)
Positive++ 33 (21.2%)
VEGF¼vascular endothelial growth factor.
Table 3 Correlation between tumour microvessel density and lymph
node metastases
Tumor microvessel density
o100 (n¼74) X100 (n¼82) P-value
a
Lymph node ratio
b
0% (n¼66) 40 26
o30% (n¼48) 18 30 o0.02
X30% (n¼42) 16 26
pN stage
c
N0 (n¼66) 40 26
N1 (n¼54) 19 35 o0.003
N2 (n¼33) 13 20
N3 (n¼3) 2 1
aw
2 test.
bNumber of affected lymph nodes divided by the total number of lymph
nodes.
cAccording to the 5th edition of the tumour-node-metastasis classification of
the International Union Against Cancer (UICC)
18;p N¼pathological lymph node.
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expression were independently associated with a shorter overall
survival (Table 6).
Influence of MVD, p53 expression, and VEGF expression
on the clinical outcome of patients receiving chemotherapy
The predictive value of MVD, p53 expression, and VEGF expres-
sion was also evaluated in the subset of 103 patients who received
adjuvant chemotherapy. As shown in Table 7, patients whose
tumours did not show p53 expression had a higher probability of
overall survival than those whose tumours presented p53
expression (P¼0.01). By contrast, MVD and VEGF expression
did not correlate with overall survival. Finally, neither MVD nor
p53 and VEGF expression predicted survival in patients who did
not receive chemotherapy (n¼53).
DISCUSSION
Surgical resection is the mainstay of treatment for gastric
cancer. However, the prognosis after resection has remained
unsatisfactory because of a high incidence of postoperative
recurrence. The identification of variables in gastric tumour
biology might lead to a more precise assessment of outcome and
response to therapy. In the present study, we investigated the
potential prognostic value of MVD, p53 expression, and VEGF
expression.
p53 expression was detected in 46% of patients, which falls
within the range (40–60%) of previously published gastric cancer
series (Joypaul et al, 1994; Gabbert et al, 1995; Victorzon et al,
1996). Use of the immunohistochemical detection of p53 as a
prognostic marker has yielded conflicting results (Fenoglio-Preiser
et al, 2003). These discrepancies may, in part, be due to the
limitations of p53 immunodetection. In fact, p53 immunoreactivity
correlates with the presence or absence of gene mutations
examined by direct sequencing in 50% of advanced gastric cancers
when exons 5–9 are examined (Tolbert et al, 1999). Technical
issues can also contribute to divergent results. In order to
overcome these limitations, we followed a meticulous methodology
using monoclonal antibody BP53-12 that is similar to antibody
DO7, antigen retrieval, and a standard counting method.
In some studies, the expression of p53 was associated with a
higher frequency of serosal, vascular, and lymphatic invasion,
increased lymph node metastases and, consequently, a more
advanced tumour stage (Kakeji et al, 1993; Kim et al, 1997; Monig
et al, 1997; Maehara et al, 1999). By contrast, other authors have
not shown the association of p53 expression with node metastases
or serosal invasion (Baba et al, 1998; Maeda et al, 1998). Our study
agrees with these latter results, since p53 expression did not
correlate to a more advanced tumour stage. In agreement with
Table 4 Influence of tumour microvessel density, p53 expression, and VEGF expression on tumor recurrence and disease-free survival (univariate analysis)
Tumour recurrence
a Disease-free survival
b
No Yes P-value OR 95% CI P-value
Microvessel density
o100 55 (74%) 19 (26%) 1
c
X100 46 (56%) 36 (44%) o0.02 2.26 1.15–4.47 0.05
p53 expression
Negative 61 (72%) 24 (28%) 1
c
Positive 40 (56%) 31 (44%) o0.05 1.96 1.01–3.83 0.09
VEGF expression
Negative 32 (80%) 8 (20%) 1
c
Positive 69 (59%) 47 (40%) o0.02 2.72 1.15–6.43 o0.02
aLogistic regression; OR¼odds ratio; 95% CI¼95% confidence interval; VEGF¼vascular endothelial growth factor.
bLog-rank test.
cReference category.
Table 5 Prognostic factors of tumour recurrence and disease-free survival (multivariate analysis)
Tumor recurrence
a Disease-free survival
b
No Yes P-value OR 95% CI P-value
Lymphadenectomy
D2 80 (75%) 26 (24%) 1
c
D1 21 (42%) 29 (58%) 0.0005 6.93 2.33–20.55 o0.0001
Lymph node ratio
0 55 (83%) 11 (17%) 1
c
o30% 32 (67%) 16 (33%) 0.06 3.11 0.95–10.16 0.13
X30% 14 (33%) 28 (67%) o0.001 9.98 2.57–38.76 o0.005
p53 expression
Negative 61 (72%) 24 (28%) 1
c
Positive 40 (56%) 31 (44%) o0.02 3.36 1.29–8.74 o0.0005
VEGF expression
Negative 32 (80%) 8 (20%) 1
c
Positive 69 (59%) 47 (40%) o0.005 5.88 1.71–20.26 o0.02
aLogistic regression; OR¼odds ratio; 95% CI¼95% confidence interval; VEGF¼vascular endothelial growth factor.
bCox’s regression.
cReference category.
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with early gastric cancer (Uchino et al, 1993), and p53 expression
has even been detected in metaplastic gastric mucosa (Ochiai et al,
1996). Thus, p53 inactivation may occur at an early stage of gastric
carcinogenesis, which explains our finding that p53 expression
indicated a poor prognosis independent of the lymph node ratio or
the depth of invasion (pT). Finally, the worse prognosis of patients
whose tumours expressed p53 may actually reflect a higher
tendency to recur. In our study, the recurrence rate in p53-
negative patients was 28% compared to 44% in p53 positive
patients (Po0.05). Similar findings have been reported in Japanese
series (Maeda et al, 1996; Maehara et al, 1999).
The prognostic role of tumour angiogenesis was also investi-
gated following a methodology accepted internationally (Vermeu-
len et al, 1996). We used a monoclonal antibody against adhesion
molecule CD34 to stain the vascular endothelium, which was found
to be superior to other markers (Tanigawa et al, 1996; Tanigawa
et al, 1998). Our study confirm’s the results of (Maeda et al, 1995)
and (Xiangming et al, 1998) showing that MVD correlates with
lymph node metastases in gastric cancer, as in esophageal cancer
(Igarashi et al, 1998). MVD was also associated with a higher
recurrence rate and a shorter disease-free survival in the univariate
analysis. However, this association was not statistically significant
in the multivariate regression analysis probably due to the positive
correlation between MVD and both p53 expression and VEGF
expression. The predictive value of MVD has also been suggested
in other studies in which a higher MVD was associated with the
development of distant metastases (Tanigawa et al, 1996) or bone
marrow micrometastases (Maehara et al, 1998). Similarly, experi-
mental studies using antiangiogenic agents, such as TNP-470, have
shown effectiveness in decreasing tumour proliferative activity and
inhibiting the development of liver and peritoneal metastases
(Kanai et al, 1997; Yoshikawa et al, 2000). These findings reinforce
the relationship between tumour angiogenesis and the spread of
metastases.
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Figure 4 (A) Overall survival in patients with VEGF-negative and VEGF-
positive tumours (Po0.02). (B) Disease-free survival in patients with
VEGF-negative and VEGF-positive tumours (Po0.02).
Table 6 Prognostic factors of overall survival (multivariate analysis)
a
Dead Alive HR 95% CI P-value
pT stage
b
T1 4 (14%) 24 (86%) 1
c
T2 16 (21%) 59 (79%) 1.18 0.37–3.78 0.77
T3 31 (58%) 22 (42%) 3.74 1.16–12.02 o0.03
Lymph node ratio
d
0 10 (15%) 56 (85%) 1
c
o30% 14 (29%) 34 (71%) 2.95 1.14–7.66 o0.03
X30% 27 (64%) 15 (36%) 7.75 3.25–18.47 o0.0001
Lymphadenectomy
D2 24 (23%) 82 (77%) 1
c
D1 27 (54%) 23 (46%) 4.40 2.30–8.44 o0.0001
Perineural invasion
Absence 44 (32%) 92 (68%) 1
c
Presence 7 (35%) 13 (65%) 2.83 1.17–6.85 o0.03
p53 expression
Negative 23 (27%) 62 (73%) 1
c
Positive 28 (39%) 43 (60%) 2.30 1.21–4.36 o0.02
VEGF expression
Negative 8 (20%) 32 (80%) 1
c
Positive 43 (37%) 73 (63%) 2.99 1.34–6.67 o0.01
aCox’s regression; HR¼hazard ratio; 95 %CI¼95% confidence interval; VEGF¼vas-
vascular endothelial growth factor; pT¼pathological tumour.
bAccording to the 5th
edition of the tumor-node metastasis classification of the International Union Against
Cancer (UICC)
18.
cReference category.
dNumber of affected lymph nodes divided by
the total number of lymph nodes.
Table 7 Influence of tumour microvessel density, p53 expression, and
VEGF expression on overall survival following adjuvant chemotherapy
Patients receiving
chemotherapy
(n¼103)
Patients not receiving
chemotherapy
(n¼53)
n
Survival
(%)
a P-value n
Survival
(%)
a P-value
Microvessel density
o100 45 76 0.58 29 31
X100 58 71 24 33 0.86
p53 expression
Negative 58 83 0.01 27 30 0.69
Positive 45 60 26 35
VEGF expression
Negative 33 82 0.16 7 43 0.52
Positive 70 69 46 30
aOverall survival at 2 years, logistic regression. VEGF¼vascular endothelial growth
factor.
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depending on the balance between activator and inhibitor factors
(Castells and Rustgi, 2003). Vascular endothelial growth factor is a
powerful and specific inducer of new vasculature in several
neoplasms. In our study, MVD correlated with VEGF expression in
tumour cells, in accordance with Maeda et al (1996). We used a
standardised method to detect VEGF expression. Our patients were
classified into two categories, by the presence or absence of
staining reaction. We decided to consider cases as positives or
negatives independent of the intensity of the staining. This fact can
justify the relatively low proportion of patients whose tumours
were considered negative for VEGF (25.6%) in the present study,
which is similar to that recently reported in other series (Song et al,
2002; Joo et al, 2003).
Vascular endothelial growth factor induces the formation of new
immature vessels, with basal membrane holes, favouring the
progression of tumour cells into the vascular space. VEGF
expression in gastric cancer has been associated with various
clinicopathological parameters such as degree of differentiation
(Tanigawa et al, 1997), intestinal-type tumours (Takahashi et al,
1996), lymphatic invasion, and vascular invasion (Maeda et al,
1996). Maehara et al (2000a) demonstrated that VEGF expression
was an independent risk factor for vascular invasion that might
account for a large number of metastases. This correlation was not
observed in our series, but it should be taken into account that it
corresponded to curatively resected patients who had a lower
probability of metastatic dissemination. However, although VEGF
expression was not associated with any tumour-related character-
istic in our study, similar as in the series of Baba et al (1998), this
parameter had an independent predictive value with respect to
tumour recurrence, disease-free survival, and overall survival.
These results suggest that VEGF expression might be a useful and
powerful prognostic marker in patients with gastric cancer
operated on for cure.
In the multivariate analysis, p53 expression and VEGF expres-
sion were independent prognostic factors. Similarly, concurrence
of p53 expression and VEGF expression occurred in only 38% of
patients, and there was no correlation between both markers. Our
results indicate that p53 and VEGF expression are important
factors to upregulate tumour angiogenesis. Whereas the role of
VEGF as an inductor of angiogenesis is well known, the
mechanism of p53 to do so is not as well established. A few
experimental studies have been published linking p53 and
angiogenesis. Kieser et al (1994) demonstrated that mutant p53
potentiates protein kinase C induction of VEGF, then promoting
the development of new vasculature. Supporting these findings,
Mukhopadhyay et al (1995) showed that wild-type p53 down-
regulated endogenous VEGF mRNA level, as well as VEGF
promoter activity, whereas mutant forms of p53 had no effect.
The authors suggested that wild-type p53 may play a role in
suppressing angiogenesis. These experimental results contrast with
those observed in clinical series. In fact, our results suggest that
p53 and VEGF regulate tumour angiogenesis in patients with
gastric cancer, but they do not support the fact that p53 stimulates
the appearance of new vasculature by enhancing the expression of
VEGF. Reviewing the literature, we found three clinical studies
with similar findings as ours, confirming that the expression of p53
does not correlate with VEGF expression in gastric cancer patients
(Baba et al, 1998; Giatromanolaki et al, 2000; Joo et al, 2002).
Preliminary studies suggested that the determination of p53
status and angiogenesis may be useful to predict response to
chemotherapy. Indeed, p53 gene inactivation by either mutation or
deletion often results in resistance to antineoplastic drugs. In these
in vitro studies, gastric and esophageal cancer cells with p53
expression were resistant to 5-fluorouracil, mitomycin-C, and
cisplatin (Lowe et al, 1994; Nabeya et al, 1995). Two clinical studies
have evaluated the influence of p53 status in patients with locally
advanced gastric cancer receiving neoadjuvant treatment. In one of
them, patients with negative p53 expression had a greater tumour
response to chemotherapy using 5-fluorouracil (72 vs 12%,
Po0.004) (Cascinu et al, 1998). Similarly, the second study found
that p53-negative and VEGF-positive patients responded better to
chemotherapy with 5-fluorouracil and cisplatin (Boku et al, 1998).
Finally, Diez et al (2000) reported in a series of 46 patients with
gastric cancer receiving adjuvant chemotherapy that the absence of
p53 overexpression was associated with longer survival. In
agreement with these observations, we demonstrated that che-
motherapy was less effective in patients whose tumours showed
p53 expression, whereas MVD and VEGF expression did not have
any predictive value in these settings. To our knowledge, this is the
largest series assessing the relationship of p53 alteration to clinical
outcome following adjuvant chemotherapy in gastric cancer, and
its results may have noteworthy clinical implications.
In conclusion, this study shows that the expression of p53,
VEGF, and a higher MVD are associated with tumour recurrence
in gastric cancer patients resected with curative intent. The
expression of p53 protein and VEGF are independent prognostic
factors of disease-free and overall survival in gastric cancer
patients having resection with curative intent. When tumour cells
express p53 protein, the therapeutic efficacy of adjuvant che-
motherapy is lost. Further studies are required to evaluate the
potential clinical applications in the management of patients with
gastric cancer.
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